Emerging Agents in Her2-positive Breast Cancer
A series of Live Grand Rounds Programs and an on-demand CME-certified Webcourse
Welcome to "Oncology Exchange: Emerging Agents in Her2-positive Breast Cancer". This CME-certified initiative is intended for oncologists and other clinicians in the community setting who are actively involved in the diagnosis, treatment, and management of patients with Her2-postitive Breast Cancer. A series of live CME-certified programs will be presented at selected hospitals throughout the US during 2012.
Community oncologists treat 80% of the cancer patients in the US each year. However, these clinicians are constantly challenged to stay up to date with emerging data from ongoing studies of novel regimens, updated clinical practice guidelines, and eligibility criteria of currently accruing trials of novel regimens for the treatment of HER2-positive breast cancer. This creates a need for educational activities to update community oncologists on recent advances in the management of HER2-positive breast cancer to improve patient outcomes.
This engaging activity is designed to meet that need, and will provide clinicians with access to new information, tools, and insights that they can integrate into their practices to improve patient outcomes.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Potomac Center for Medical Education and Rockpointe Oncology. Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email firstname.lastname@example.org.
A calendar of live events, as well as additional CME-certified online activities, for this and other Oncology Exchange initiatives can be found at: www.medscape.org/viewcollection/32391.
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the 2012 Visiting Professor Series, "Oncology Exchange: Emerging Agents in Her2-positive Breast Cancer." This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
- Review the recently updated clinical practice guidelines for HER2-positive breast cancer
- Discuss recent data with HER2-targeted agents in the neoadjuvant and adjuvant settings and choose the optimal treatment for patients with early-stage HER2-positive breast cancer and patients with abnormal cytogenetics
- Assess the various treatment strategies for patients with locally advanced or metastatic HER2-positive breast cancer
- Identify eligibility criteria and the status of currently accruing clinical trials in HER2-positive breast cancer and counsel patients accordingly
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
CME-certified Program Slides
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
Debu Tripathy, MD
Professor of Medicine
University of Southern California
Co-Leader, Women’s Cancer Program
USC/Norris Comprehensive Cancer Center
Los Angeles, CA
Debu Tripathy, MD is Professor of Clinical Medicine and Co-leader of the Women’s Cancer Program, and holds the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California and USC/Norris Comprehensive Cancer Center. He received a degree in chemical engineering from the Massachusetts Institute of Technology and then completed medical school and an internal medicine residency at Duke University, followed by a hematology/oncology fellowship at the University of California at San Francisco.
His clinical research focuses on the evaluation and development of novel therapeutics in breast cancer, specifically, growth factor receptor pathway targeting, as well as biomarkers that predict sensitivity and resistance. Elucidation of specific mechanisms of resistance and synthetic lethal combinatorial strategies from the laboratory are being applied for early phase therapeutic applications. Similarly, human tissue studies from patients receiving conventional and targeted therapies are being analyzed toward the discovery of novel targets and predictive biomarkers.
Dr. Tripathy is also part of a multi-disciplinary team of breast cancer specialists dedicated to patient-centered state-of-the-art and personalized approaches to care, with an emphasis on clinical trials that interface with the basic scientific strengths at USC and external collaborators. Dr. Tripathy has published numerous original laboratory and clinical research articles on breast cancer and serves on several editorial boards, study sections, and society boards, as well as being Editor-in-Chief of CURE Magazine. He has previously served as the President of the American Society of Breast Disease and the Society of Integrative Oncology.
Kathy Miller, MD
Sheila D Ward Scholar
IU Simon Cancer Center
Kathy Miller, MD’s career focuses on translational clinical research in breast cancer. She became Co-chair of the Eastern Cooperative Oncology Group Breast Core Committee in 2010. In this role, she has worked with laboratory scientists and community oncologists to develop trials that combine clinical and biologic endpoints, but remain feasible in non-academic settings.
Dr. Miller first honed her ability to coordinate multi-center trials as Principal Investigator for E2100, the first phase III trial to confirm the benefits of antiangiogenic therapy in patients with metastatic breast cancer. Dr. Miller currently leads E5103, an international phase III trial investigating antiangiogenic therapy in the adjuvant setting. Preclinical studies suggest that inhibition of telomerase may reverse resistance to trastuzumab in patients with HER2-positive breast cancer. Dr. Miller brings these findings to the clinic with the first phase I trial of a telomerase inhibitor and trastuzumab in trastuzumab-resistant patients.